Portfolio
Corner Office
Culture
Premium
Opinion
Research
Video
Innovation
Menu
Subscribe
Sign In
Register
Portfolio
Corner Office
Culture
Premium
Opinion
Research
Video
Innovation
Search Query
Submit Search
Show Search
Philidor
Premium
Valeant’s Winners and Losers
The troubled drugmaker takes another plunge as it reduces guidance. Here’s a quick survey of the firms that are taking a bath and those that look like geniuses.
Stephen Taub
March 16, 2016
Portfolio
Daily Agenda: Liquidity Fuels Continuing M&A Boom
A bid by Pfizer for Allergan would be the year’s biggest deal; Valeant distances itself from Philidor; Budget deal passed in Congress.
Andrew Barber
October 30, 2015